Galectin Therapeutics (GALT) Times Interest Earned (2018 - 2026)
Galectin Therapeutics (GALT) recorded quarterly Times Interest Earned of -$2.05 in Q1 2026, down 18.17% quarter-over-quarter from -$1.74 in Q4 2025, and up 54.71% on a YoY basis from -$1.33 in Q1 2025.
Galectin Therapeutics (GALT) Times Interest Earned (2018 - 2026) Analysis & Trends
Galectin Therapeutics' Times Interest Earned history runs 9 years deep, the most recent figure standing at -$2.05 for Q1 2026.
- In Q1 2026, Times Interest Earned rose 54.71% year-over-year to -$2.05; the TTM figure through Mar 2026 stood at -$2.15 (up 67.1% YoY), while the FY2025 annual figure was -$2.74, up 64.22% from the prior year.
- Times Interest Earned was -$2.05 for Q1 2026 at Galectin Therapeutics, down from -$1.74 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$1.74 in Q4 2025 to a low of -$43.77 in Q1 2022.
- Historically, Times Interest Earned has averaged -$14.93 across 5 years, with a median of -$9.17 in 2024.
- Biggest YoY gain for Times Interest Earned was 97.44% in 2022; the steepest drop was 26.47% in 2022.
- A 5-year view of Times Interest Earned shows it stood at -$34.52 in 2022, then jumped by 67.3% to -$11.29 in 2023, then surged by 36.17% to -$7.2 in 2024, then soared by 75.91% to -$1.74 in 2025, then declined by 18.17% to -$2.05 in 2026.
- The last three Times Interest Earned figures came in at -$2.05 (Q1 2026), -$1.74 (Q4 2025), and -$2.31 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 11.50 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -258.33 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 11.79 |
| 10 | Galectin Therapeutics | 185.83 Mn | 171.73 Mn | - | -2.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.05 |
| Dec 31, 2025 | -1.74 |
| Sep 30, 2025 | -2.31 |
| Jun 30, 2025 | -2.53 |
| Mar 31, 2025 | -4.53 |
| Dec 31, 2024 | -7.20 |
| Sep 30, 2024 | -6.07 |
| Jun 30, 2024 | -8.90 |
| Mar 31, 2024 | -9.17 |
| Dec 31, 2023 | -11.29 |
| Sep 30, 2023 | -10.98 |
| Jun 30, 2023 | -13.85 |
| Mar 31, 2023 | -22.48 |
| Dec 31, 2022 | -34.52 |
| Sep 30, 2022 | -30.19 |
| Jun 30, 2022 | -42.19 |
| Mar 31, 2022 | -43.77 |
| Dec 31, 2021 | -27.30 |
| Sep 30, 2021 | -1,177.71 |
| Jun 30, 2021 | -96.39 |